KFGK
LRMR icon

Keystone Financial Group (Kentucky)’s Larimar Therapeutics LRMR Stock Holding History

Keystone Financial Group (Kentucky)’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.6K Hold
13,000
– – ﹤0.01% 558
2026
Q1 		$58.5K Hold
13,000
– – ﹤0.01% 510
2025
Q4 		$49.5K Buy
+13,000
New +$50.6K ﹤0.01% 448
2025
Q3 		– Sell
-13,000
Closed -$37.6K – 459
2025
Q2 		$37.6K Buy
+13,000
New +$30.1K ﹤0.01% 424

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Keystone Financial Group (Kentucky)'s LRMR Position: Q2 2026 in Review

Keystone Financial Group (Kentucky) held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 13,000 shares worth $39.6K. The position accounts for ﹤0.01% of the portfolio, ranked #558.

Keystone Financial Group (Kentucky) first reported a position in LRMR in Q2 2025 and has held it in 4 quarters since. The position peaked at $58.5K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Keystone Financial Group (Kentucky) held 13,000 shares of Larimar Therapeutics worth $39.6K as of Q2 2026.
  • Keystone Financial Group (Kentucky) left its Larimar Therapeutics share count unchanged in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Keystone Financial Group (Kentucky)'s portfolio in Q2 2026, its #558 holding.
  • Keystone Financial Group (Kentucky) first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Keystone Financial Group (Kentucky)'s Larimar Therapeutics position peaked at $58.5K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Keystone Financial Group (Kentucky)'s 13F filing for Q2 2026, filed 29 Jul 2026.